In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...
Hosted on MSN
He poisoned her protein shakes!
A US dentist who poisoned his wife has been sentenced to life in prison without parole after a Colorado jury found him guilty of murder and other charges. James Craig, 47, had been having an affair ...
Chipotle and protein fans, it’s time to get excited! Chipotle unveiled its new High Protein Menu on Dec. 18, available to order starting Dec. 23 in the U.S. and Canada. With a new snack cup, bowl and ...
The plant-based milk category heads into 2026 with momentum – both from Washington and from brands rethinking taste, nutrition and functionality, according to the Plant-Based Foods Association (PBFA).
UCSF's Dr Laura Huppert explores a phase 2 trial assessing ARX788's safety and efficacy for HER2-low breast cancer patients, targeting unmet clinical needs. Laura Huppert, MD, UCSF, discusses the ...
The FDA has approved trastuzumab deruxtecan (T-DXd; Enhertu, Daiichi Sankyo/AstraZeneca) in combination with pertuzumab for the first-line treatment of unresectable or metastatic HER2-positive breast ...
The Food and Drug Administration on Monday granted a key approval for AstraZeneca and Daiichi Sankyo’s Enhertu, clearing a regimen involving the drug as an initial treatment for HER2-positive breast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback